机构：[1]Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany[2]Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research, Tübingen, Germany[3]The Parkinson’s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA[4]Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands[5]Xuanwu Hospital of Capitol of Medical University, Beijing, Peoples Republic of China首都医科大学宣武医院[6]Rush University Medical Center, Chicago, Illinois, USA[7]Neuroscience Research Australia & University of New South Wales, Randwick, Australia[8]Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada[9]Brain and Mind Centre University of Sydney, Camperdown, Australia[10]German Center for Neurodegenerative Diseases, Tübingen, Germany[11]Department of Neurosciences, University of California San Diego, La Jolla, California, USA[12]Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA[13]University of Navarra-Fundación para la Investigación Médica Aplicada (FIMA), Pamplona, Spain[14]Department of Neurology, Philipps University of Marburg, Marburg, Germany[15]Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA[16]Department of Neurology, Innsbruck Medical University, Innsbruck, Austria[17]Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada[18]Penn Neurological Institute, Philadelphia, Pennsylvania, USA[19]University of California, San Francisco, California, USAreal,Canada H3G1A4
Background: In 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD. Objectives: The objective of this study was to generate and test a PD diagnostic criteria termed clinically established early PD. Methods: We modified the Movement Disorder Society criteria to increase specificity for early PD by removing all disease duration components and changing red flags to absolute exclusions. We then estimated the sensitivity/specificity of clinically established early PD criteria in patients with disease duration <5 years, selected from a 626-patient validation study. Results: After documentation of parkinsonism, 18 individual exclusion criteria are assessed that preclude the diagnosis of clinically established early PD. Among 212 PD and 152 non-PD patients, the estimated specificity was 95.4%, with 69.8% sensitivity. Conclusions: We describe high-specificity criteria for de novo PD, which are freely available for use in clinical trials. (c) 2018 International Parkinson and Movement Disorder Society
基金：
1Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany 2Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research, Tübingen, Germany 3The Parkinson’s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA 4Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands 5Xuanwu Hospital of Capitol of Medical University, Beijing, Peoples Republic of China 6Rush University Medical Center, Chicago, Illinois, USA 7Neuroscience Research Australia & University of New South Wales, Randwick, Australia 8Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada 9Brain and Mind Centre University of Sydney, Camperdown, Australia 10German Center for Neurodegenerative Diseases, Tübingen, Germany 11Department of Neurosciences, University of California San Diego, La Jolla, California, USA 12Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA 13University of Navarra-Fundación para la Investigación Médica Aplicada (FIMA), Pamplona, Spain 14Department of Neurology, Philipps University of Marburg, Marburg, Germany 15Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA 16Department of Neurology, Innsbruck Medical University, Innsbruck, Austria 17Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada 18Penn Neurological Institute, Philadelphia, Pennsylvania, USA 19University of California, San Francisco, California, USA
第一作者机构：[1]Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany[2]Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research, Tübingen, Germany[*2]Department of Neurology, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3 24105 Kiel
通讯作者：
通讯机构：[*1]Department of Neurology,L7-305 Montreal General Hospital, 1650 Cedar Ave, Montreal,Canada H3G1A4[*2]Department of Neurology, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3 24105 Kiel
推荐引用方式(GB/T 7714)：
Daniela Berg,Charles H. Adler,Bastiaan R. Bloem,et al.Movement disorder society criteria for clinically established early Parkinson's disease[J].MOVEMENT DISORDERS.2018,33(10):1643-1646.doi:10.1002/mds.27431.
APA：
Daniela Berg,Charles H. Adler,Bastiaan R. Bloem,Piu Chan,Thomas Gasser...&Ronald B. Postuma.(2018).Movement disorder society criteria for clinically established early Parkinson's disease.MOVEMENT DISORDERS,33,(10)
MLA：
Daniela Berg,et al."Movement disorder society criteria for clinically established early Parkinson's disease".MOVEMENT DISORDERS 33..10(2018):1643-1646
医学